EGEsther Shuyi Gan

Esther Shuyi Gan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Esther Shuyi Gan has a total of 134 co-authors. Here are the top co-authors by number of shared publications:

  • Eng Eong Ooi

    Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore

    17 shared publications
  • Hwee Cheng Tan

    Duke NUS Med Sch, Program Emerging Infect Dis, 8 Coll Rd, Singapore 169857, Singapore

    9 shared publications
  • Eugenia Ziying Ong

    Emerging Infectious Diseases Programme, Duke-NUS Medical School, Singapore, Singapore

    5 shared publications
  • Jenny Guek Hong Low

    Programme in Emerging Infectious Diseases, Duke-NUS Medical School, College Road, 169857, Singapore; Viral Research and Experimental Medicine Centre (ViREMiCS), SingHealth Duke-NUS Academic Medical Centre, 169856, Singapore; Department of Infectious Diseases, Singapore General Hospital, Outram Road, 169608, Singapore

    4 shared publications
  • Kuan Rong Chan

    Programme in Emerging Infectious Diseases, Duke-National University of Singapore Medical School, Singapore, 169857, Singapore

    4 shared publications
  • Kuan Rong Chan

    Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore

    4 shared publications

Latest Publications

  • Open Access

    A mouse model of lethal respiratory dysfunction for SARS-CoV-2 infection

    by Esther S. Gan, Ayesa Syenina, Martin Linster, Benson Ng, Summer L. Zhang, Satoru Watanabe, Ravisankar Rajarethinam, Hwee Cheng Tan, Gavin Jd. Smith, Eng Eong Ooi


  • Open Access

    Aviremic organ transplant dengue virus transmission – A case report

    by Jean Xiang Ying Sim, Esther Shuyi Gan, Hwee Cheng Tan, Milly M. Choy, Hei Man Wong, Ban Hock Tan, Terence Kee, Quan Yao Ho, Sobhana Thangaraju, Raymond Tzer Pin Lin, et al.


  • Open Access

    A Single Dose of Self-Transcribing and Replicating RNA Based SARS-CoV-2 Vaccine Produces Protective Adaptive Immunity In Mice

    by Ruklanthi M de Alwis, Esther S Gan, Shiwei Chen, Yan Shan Leong, Hwee Cheng Tan, Summer L. Zhang, Clement Yau, Daiki Matsuda, Elizabeth Allen, Paula Hartman, et al.

    A self-transcribing and replicating RNA (STARR™) based vaccine (LUNAR ® -COV19) has been developed to prevent SARS-CoV-2 infection. The vaccine encodes an alphavirus-based replicon and the SARS-CoV-2 full length spike glycoprotein. Translation of the replicon produces a replicase complex that amplifies and prolong SARS-CoV-2 spike glycoprotein expression. A single prime vaccination in mice led to robust antibody responses, with neutralizing antibody titers increasing up to day 60. Activation of cell mediated immunity produced a strong viral antigen specific CD8 + T lymphocyte response. Assaying for intracellular cytokine staining for IFN-γ and IL-4 positive CD4 + T helper lymphocytes as well as anti-spike glycoprotein IgG2a/IgG1 ratios supported a strong Th1 dominant immune response. Finally, single LUNAR-COV19 vaccination at both 2 μg and 10 μg doses completely protected human ACE2 transgenic mice from both mortality and even measurable infection following wild-type SARS-CoV-2 challenge. Our findings collectively suggest the potential of Lunar-COV19 as a single dose vaccine.


  • Open Access

    Dengue virus induces PCSK9 expression to alter antiviral responses and disease outcomes

    by Esther Shuyi Gan, Hwee Cheng Tan, Duyen Huynh Thi Le, Trieu Trung Huynh, Bridget Wills, Nabil G. Seidah, Eng Eong Ooi, Sophie Yacoub

    Dengue virus (DENV) infection requires cholesterol as a proviral factor, although statin treatment did not show antiviral efficacy in patients with dengue. Here, we show that DENV infection manipulated cholesterol metabolism in cells residing in low-oxygen microenvironments (hypoxia) such as in the liver, spleen, and lymph nodes. DENV infection induced expression of proprotein convertase subtilisin/kexin type 9 (PCSK9), which reduces low-density lipoprotein receptor (LDLR) recycling and hence cholesterol uptake. We found that, whereas LDLR uptake would have distributed cholesterol throughout the various cell compartments, de novo cholesterol synthesis enriched this lipid in the endoplasmic reticulum (ER). With cholesterol enrichment in the ER, ER-resident STING and type I IFN (IFN) activation was repressed during DENV infection. Our in vitro findings were further supported by the detection of elevated plasma PCSK9 levels in patients with dengue with high viremia and increased severity of plasma leakage. Our findings therefore suggest that PCSK9 plays a hitherto unrecognized role in dengue pathogenesis and that PCSK9 inhibitors could be a suitable host-directed treatment for patients with dengue.


  • Open Access

    Oxygen: viral friend or foe?

    by Esther Shuyi Gan, Eng Eong Ooi

    The oxygen levels organ and tissue microenvironments vary depending on the distance of their vasculature from the left ventricle of the heart. For instance, the oxygen levels of lymph nodes and the spleen are significantly lower than that in atmospheric air. Cellular detection of oxygen and their response to low oxygen levels can exert a significant impact on virus infection. Generally, viruses that naturally infect well-oxygenated organs are less able to infect cells under hypoxic conditions. Conversely, viruses that infect organs under lower oxygen tensions thrive under hypoxic conditions. This suggests that in vitro experiments performed exclusively under atmospheric conditions ignores oxygen-induced modifications in both host and viral responses. Here, we review the mechanisms of how cells adapt to low oxygen tensions and its impact on viral infections. With growing evidence supporting the role of oxygen microenvironments in viral infections, this review highlights the importance of factoring oxygen concentrations into in vitro assay conditions. Bridging the gap between in vitro and in vivo oxygen tensions would allow for more physiologically representative insights into viral pathogenesis.


  • Open Access

    Positive epistasis between viral polymerase and the 3′ untranslated region of its genome reveals the epidemiologic fitness of dengue virus

    by Ayesa Syenina, Dhanasekaran Vijaykrishna, Esther Shuyi Gan, Hwee Cheng Tan, Milly M. Choy, Tanamas Siriphanitchakorn, Colin Cheng, Subhash G. Vasudevan, Eng Eong Ooi

    Significance: Dengue affects approximately one-half of the world’s population. While it causes regular and cyclical outbreaks throughout the tropical world, the molecular mechanisms that determine its epidemic potential remain poorly defined. The present work provides insight into the molecular determinants of epidemiologic fitness, which is critical for surveillance to identify dengue virus strains with a potential to cause outbreaks. This will allow for better implementation of control measures to intercept impending outbreaks before many lives are affected.


  • Open Access

    Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development

    by Ruklanthi de Alwis, Shiwei Chen, Esther S. Gan, Eng Eong Ooi


  • Open Access

    Antibody-Dependent Dengue Virus Entry Modulates Cell Intrinsic Responses for Enhanced Infection

    by Candice Y. Y. Chan, John Zhong Heng Low, Esther Shuyi Gan, Eugenia Ziying Ong, Summer Li-Xin Zhang, Hwee Cheng Tan, Xiaoran Chai, Sujoy Ghosh, Eng Eong Ooi, Kuan Rong Chan

    Dengue virus is the most prevalent mosquito-borne viral infection globally, resulting in variable manifestations ranging from asymptomatic viremia to life-threatening shock and multiorgan failure. Previous studies have indicated that the risk of severe dengue in humans can be increased by a specific range of preexisting anti-dengue virus antibody titers, a phenomenon termed antibody-dependent enhancement. There is hence a need to understand how antibodies augment dengue virus infection compared to the alternative canonical receptor-mediated viral entry route. Herein, we show that, besides facilitating viral uptake, antibody-mediated entry increases the expression of early host dependency factors to promote viral infection; these factors include RNA splicing, mitochondrial respiratory chain complexes, vesicle trafficking, and ribosomal genes. These findings will enhance our understanding of how differences in entry pathways can affect host responses and offer opportunities to design therapeutics that can specifically inhibit antibody-dependent enhancement of dengue virus infection.


  • Metabolic perturbations and cellular stress underpin susceptibility to symptomatic live-attenuated yellow fever infection

    by Kuan Rong Chan, Esther Shuyi Gan, Candice Yuen Yue Chan, Cui Liang, John Zhong Heng Low, Summer Li-Xin Zhang, Eugenia Ziying Ong, Ashwin Bhatta, Limin Wijaya, Yie Hou Lee, et al.

    Flaviviral infections result in a wide spectrum of clinical outcomes, ranging from asymptomatic infection to severe disease. Although the correlates of severe disease have been explored1-4, the pathophysiology that differentiates symptomatic from asymptomatic infection remains undefined. To understand the molecular underpinnings of symptomatic infection, the blood transcriptomic and metabolomic profiles of individuals were examined before and after inoculation with the live yellow fever viral vaccine (YF17D). It was found that individuals with adaptive endoplasmic reticulum (ER) stress and reduced tricarboxylic acid cycle activity at baseline showed increased susceptibility to symptomatic outcome. YF17D infection in these individuals induced maladaptive ER stress, triggering downstream proinflammatory responses that correlated with symptomatic outcome. The findings of the present study thus suggest that the ER stress response and immunometabolism underpin symptomatic yellow fever and possibly even other flaviviral infections. Modulating either ER stress or metabolism could be exploited for prophylaxis against symptomatic flaviviral infection outcome.


  • Open Access

    Identification and in vivo Efficacy Assessment of Approved Orally Bioavailable Human Host Protein-Targeting Drugs With Broad Anti-influenza A Activity

    by Theresa Enkirch, Svenja Sauber, Danielle E. Anderson, Esther S. Gan, Dimitar Kenanov, Sebastian Maurer-Stroh, Veronika von Messling

    The high genetic variability of influenza A viruses poses a continual challenge to seasonal and pandemic vaccine development, leaving antiviral drugs as the first line of defense against antigenically different strains or new subtypes. As resistance against drugs targeting viral proteins emerges rapidly, we assessed the antiviral activity of already approved drugs that target cellular proteins involved in the viral life cycle and were orally bioavailable. Out of 15 candidate compounds, four were able to inhibit infection by 10- to 100-fold without causing toxicity, in vitro. Two of the drugs, dextromethorphan and ketotifen, displayed a 50% effective dose between 5 and 50 μM, not only for the classic H1N1 PR8 strain, but also for a pandemic H1N1 and a seasonal H3N2 strain. Efficacy assessment in mice revealed that dextromethorphan consistently resulted in a significant reduction of viral lung titers and also enhanced the efficacy of oseltamivir. Dextromethorphan treatment of ferrets infected with a pandemic H1N1 strain led to a reduction in clinical disease severity, but no effect on viral titer was observed. In addition to identifying dextromethorphan as a potential influenza treatment option, our study illustrates the feasibility of a bioinformatics-driven rational approach for repurposing approved drugs against infectious diseases.